Patrick O Brien, MD
Physical Medicine & Rehabilitation · Raleigh, NCNPI 1356374219
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,646 of the $85,665 with a category attached, or 91.8%. AbbVie accounts for 97.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2021 at $24,815 and has fallen 66.0% since, to $8,427 in 2025. Among physical medicine & rehabilitation clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $478.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Medtronic$477
- Johnson & Johnson$268
- Otsuka America Pharmaceutical, Inc.$204
- Sunovion Pharmaceuticals Inc.$197
- UCB, Inc.$149
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$78,64692%
- Travel & lodging$3,4884%
- Food & beverage$3,5164%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $83,315 |
| Medtronic | 6 | $477 |
| Johnson & Johnson | 12 | $268 |
| Otsuka America Pharmaceutical, Inc. | 9 | $204 |
| Sunovion Pharmaceuticals Inc. | 14 | $197 |
| UCB, Inc. | 5 | $149 |
| Microtransponder, Inc. | 1 | $131 |
| Neurocrine Biosciences, Inc. | 2 | $122 |
| Avanir Pharmaceuticals, Inc. | 6 | $122 |
| Lundbeck LLC | 5 | $109 |
| Amarin Pharma, Inc. | 5 | $87 |
| Neurelis, Inc. | 3 | $85 |
| Acadia Pharmaceuticals Inc | 3 | $56 |
| Novartis | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 4 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Smith+Nephew | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Masimo Corporation | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$82,173
- SYNCHROMEDII$430
- XARELTO$112
- INGREZZA$100
How this compares
$85,665 in reported general payments places this provider in the 95th percentile of 269 physical medicine & rehabilitation providers in North Carolina.
See all physical medicine & rehabilitation providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 3,453 | $891,912 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 71 | $294,550 |
| IngrezzaValbenazine Tosylate | 21 | $179,986 |
| TrulicityDulaglutide | 336 | $177,877 |
| XareltoRivaroxaban | 500 | $130,363 |
| JardianceEmpagliflozin | 404 | $104,111 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 171 | $102,344 |
| TradjentaLinagliptin | 534 | $99,676 |
| NuplazidPimavanserin Tartrate | 51 | $97,927 |
| EntrestoSacubitril/Valsartan | 286 | $86,043 |
| SantylCollagenase Clostridium Hist. | 88 | $73,978 |
| Atorvastatin Calcium | 5,188 | $70,729 |
| TivicayDolutegravir Sodium | 28 | $66,642 |
| LinzessLinaclotide | 111 | $64,317 |
| AptiomEslicarbazepine Acetate | 76 | $64,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $122 | $179,98621 claims |
| Lilly USA, LLCTrulicity | $15 | $177,877336 claims |
| AbbVieLinzess, Creon, Restasis | $83,315 | $167,542257 claims |
| Johnson & JohnsonXarelto | $268 | $130,363500 claims |
| AstraZenecaFarxiga, Lokelma | $18 | $100,492319 claims |
| Acadia Pharmaceuticals IncNuplazid | $56 | $97,92751 claims |
| NovartisEntresto | $48 | $86,043286 claims |
| Smith+NephewSantyl | $19 | $73,97888 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $197 | $64,06276 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $204 | $36,32812 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $24 | $32,17816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 269 physical medicine & rehabilitation providers in North Carolina.
Other physical medicine & rehabilitation in Raleigh
- Emmanuel SaklaRaleigh$9K
- Mark ReznikRaleigh$6K
- Derek WatsonRaleigh$2K
- Andrew SumichCharlotte$181K
- Elizabeth BagsbyGreenville$33K
- Krishna BhatSanford$30K
- Jasbir DhaliwalSanford$23K
- Jimmy MaliDurham$20K
- Jerome WatsonStatesville$15K
- Tejas ParikhGastonia$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.